Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Century Therapeutics ( (IPSC) ) just unveiled an announcement.
Century Therapeutics has released an updated corporate presentation detailing its progress in developing iPSC-derived cell therapies, including the lead product candidate CNTY-101, which targets B-cell malignancies and autoimmune diseases. The company highlights its advanced Allo-Evasion technology, which enhances immune evasion and allows repeat dosing without lymphodepletion, positioning Century as a leader in the field and potentially impacting its competitive standing in the biotechnology market.
More about Century Therapeutics
Century Therapeutics operates in the biotechnology industry, focusing on the development of induced pluripotent stem cell (iPSC) derived therapies. The company is notable for its Allo-Evasion technology which enhances immune evasion capabilities, allowing for repeat dosing and improved treatment outcomes in cancer and autoimmune diseases.
YTD Price Performance: -4.81%
Average Trading Volume: 580,134
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $84.18M
For detailed information about IPSC stock, go to TipRanks’ Stock Analysis page.
